Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma

Leukemia and Lymphoma

Volumn 54, Issue 9, 2013, Pages 1975-1981

  Brioli, Annamaria ^a,b   Kaiser, Martin F ^a   Pawlyn, Charlotte ^a   Wu, Ping ^a   Gregory, Walter M ^c   Owen, Roger ^d   Ross, Fiona M ^e   Jackson, Graham H ^f   Cavo, Michele ^b   Davies, Faith E ^a   Morgan, Gareth J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Biological subtypes; Chemotherapeutic approach; Cytogenetics; Maintenance; Myeloma; Thalidomide

Indexed keywords

THALIDOMIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HIGH RISK POPULATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IN SITU HYBRIDIZATION, FLUORESCENCE; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; THALIDOMIDE; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84882991489     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.760736     Document Type: Article

References (18)

1. Interferon as therapy for multiple myeloma:An individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001;113:1020-1034.
2. Shustik C, Belch A, Robinson S, et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma:NCIC CTG MY.7. Br J Haematol 2007;136:203-211.
3. Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stemcell transplantation:MRC Myeloma IX randomized trial results. Haematologica 2012;97:442-450.
4. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma :A randomised phase 3 s tudy. Lancet 2010;376:2075-2085.
5. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma:An open-label randomised controlled trial. Lancet Oncol 2010;11:29-37.
6. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289-3294.
7. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009;27:1788-1793.
8. Sonneveld P, Schmidt-Wolf I G, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30:2946-2955.
9. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782-1791.
10. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770-1781.
11. Barlogie B, Pineda-Roman M, van Rhee F, et al. Th alidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008;112:3115-3121.
12. Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma:MRC Myeloma IX results and meta-analysis. Blood 2012;119:7-15.
13. Ludwig H, Durie BG, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012;119:3003-3015.
14. Hahn-Ast C, von Lilienfeld-Toal M, van Heteren P, et al. Improved progression-free and overall survival with thalidomide maintenance therapy after autologous stem cell transplantation in multiple myeloma :A meta-analysis of five randomized trials. Haematologica 2011;96(s2):Abstract 2884.
15. Boyd K D, Ross F M, Chiecchio L, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS:Analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012;26:349-355.
16. Chiecchio L, Protheroe RK, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006;20:1610-1617.
17. Barlogie B, Attal M, Crowley J, et al. Long-term follow-up of autotransplantation trials for multiple myeloma: Update of protocols conducted by the Intergroupe Francophone DU Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol 2010;28:1209-1214.
18. Barlogie B, Anaissie E, van Rhee F, et al. Reiterative survival analyses of Total Therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. J Clin Oncol 2010;28:3023-3027.